I/O player iTeos lines up a $75M round as it preps for human studies, plans a leap to US hub
The Belgian biotech iTeos is finding out just how generous investors can be when it comes to backing a new drug that might play a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
